R.J. Hohl

848 total citations
10 papers, 184 citations indexed

About

R.J. Hohl is a scholar working on Hematology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, R.J. Hohl has authored 10 papers receiving a total of 184 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Hematology, 3 papers in Molecular Biology and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in R.J. Hohl's work include Erythropoietin and Anemia Treatment (4 papers), Bladder and Urothelial Cancer Treatments (2 papers) and Blood groups and transfusion (2 papers). R.J. Hohl is often cited by papers focused on Erythropoietin and Anemia Treatment (4 papers), Bladder and Urothelial Cancer Treatments (2 papers) and Blood groups and transfusion (2 papers). R.J. Hohl collaborates with scholars based in United States, India and France. R.J. Hohl's co-authors include Robert L. Schmidt, John A. Widness, P. Veng‐Pedersen, Sunny Chapel, Nidal Al‐Huniti, Susan Halabi, Jonathan E. Rosenberg, Ben L. Sanford, Dean F. Bajorin and Andrew L. Himelstein and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

R.J. Hohl

10 papers receiving 181 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
R.J. Hohl United States	8	105	50	38	31	29	10	184
Yao‐Chung Liu Taiwan	11	115 1.1×	73 1.5×	64 1.7×	17 0.5×	34 1.2×	32	288
H. Abid Tunisia	11	62 0.6×	100 2.0×	55 1.4×	27 0.9×	17 0.6×	29	257
Brenda Gibson United Kingdom	8	196 1.9×	93 1.9×	64 1.7×	8 0.3×	42 1.4×	20	305
Yash Pal Agrawal Finland	10	41 0.4×	60 1.2×	26 0.7×	33 1.1×	10 0.3×	15	203
Ramzi Jeddi Tunisia	10	115 1.1×	99 2.0×	77 2.0×	5 0.2×	26 0.9×	24	248
Gilles Avenard France	7	132 1.3×	47 0.9×	8 0.2×	30 1.0×	7 0.2×	17	277
Cheryl Goss United States	7	87 0.8×	21 0.4×	29 0.8×	10 0.3×	51 1.8×	15	187
Nicola Alcorn United Kingdom	4	32 0.3×	45 0.9×	22 0.6×	14 0.5×	21 0.7×	6	205
Bruno Deltreggia Benites Brazil	9	110 1.0×	66 1.3×	18 0.5×	5 0.2×	104 3.6×	40	237
B.R. Bacon United States	7	161 1.5×	34 0.7×	10 0.3×	13 0.4×	127 4.4×	15	360

Countries citing papers authored by R.J. Hohl

Since Specialization

Citations

This map shows the geographic impact of R.J. Hohl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R.J. Hohl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R.J. Hohl more than expected).

Fields of papers citing papers by R.J. Hohl

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R.J. Hohl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R.J. Hohl. The network helps show where R.J. Hohl may publish in the future.

Co-authorship network of co-authors of R.J. Hohl

This figure shows the co-authorship network connecting the top 25 collaborators of R.J. Hohl. A scholar is included among the top collaborators of R.J. Hohl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R.J. Hohl. R.J. Hohl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

Gronchi, Alessandro, Axel Le Cesne, N.B. Bui, et al.. (2009). A phase II clinical trial of neoadjuvant trabectedin in patients with nonmetastatic advanced myxoid/round cell liposarcoma (MRCL). Journal of Clinical Oncology. 27(15_suppl). 10525–10525. 7 indexed citations

Rosenberg, Jonathan E., Susan Halabi, Ben L. Sanford, et al.. (2008). Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207. Annals of Oncology. 19(5). 946–950. 39 indexed citations

Widness, John A., Robert L. Schmidt, R.J. Hohl, et al.. (2007). Change in Erythropoietin Pharmacokinetics Following Hematopoietic Transplantation. Clinical Pharmacology & Therapeutics. 81(6). 873–879. 21 indexed citations

Siegel, David S., A. Krishnan, Sagar Lonial, et al.. (2006). Phase II Trial of SCIO-469 as Monotherapy (M) or in Combination with Bortezomib (MB) in Relapsed Refractory Multiple Myeloma (MM).. Blood. 108(11). 3580–3580. 16 indexed citations

Rosenberg, Jonathan E., Susan Halabi, Ben L. Sanford, et al.. (2006). CALGB 90207: Phase II trial of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma (TCC). Journal of Clinical Oncology. 24(18_suppl). 4582–4582. 3 indexed citations

Veng‐Pedersen, P., Sunny Chapel, Nidal Al‐Huniti, et al.. (2004). Pharmacokinetic tracer kinetics analysis of changes in erythropoietin receptor population in phlebotomy‐induced anemia and bone marrow ablation. Biopharmaceutics & Drug Disposition. 25(4). 149–156. 21 indexed citations

Veng‐Pedersen, P., Sunny Chapel, Nidal Al‐Huniti, et al.. (2003). A Differential Pharmacokinetic Analysis of the Erythropoietin Receptor Population in Newborn and Adult Sheep. Journal of Pharmacology and Experimental Therapeutics. 306(2). 532–537. 7 indexed citations

Hohl, R.J., et al.. (2003). Orange juice decreases the oral bioavailability of ivermectin in healthy volunteers. Clinical Pharmacology & Therapeutics. 73(2). 15 indexed citations

Chapel, Sunny, et al.. (2001). Changes in Erythropoietin Pharmacokinetics following Busulfan-Induced Bone Marrow Ablation in Sheep: Evidence for Bone Marrow as a Major Erythropoietin Elimination Pathway. Journal of Pharmacology and Experimental Therapeutics. 298(2). 820–824. 53 indexed citations

10.

Kastrissios, Helen, Cynthia G. Leichman, Donna Hollis, et al.. (2001). Phase 1 study of irinotecan (CPT-11) in patients with abnormal liver or renal function or with prior pelvic radiation therapy. Queensland's institutional digital repository (The University of Queensland). 2001(20). 293–293. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact